The problem at the heart of drug discovery: Lexogen & Ochre Bio on the power of AI on human data

Today I am welcoming two guests: Quin Wills, CEO of Ochre Bio, a biotech developing RNA therapies for chronic liver disease using AI models, and Stéphane Barges, CEO of Lexogen, an RNA transcriptomics company and NGS service provider. It’s a deep dive into cutting edge transcriptomics, human-first data, and artificial intelligence. 00:55: The challenges of liver disease 04:44: How Lexogen supports NGS drug discovery 07:29: Major transcriptomics developments 10:05: Designing high quality AI da...